Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease
Haoping Sun(University of Maryland, Baltimore), Xiaoyu Zhang(Agilent Technologies (United States)), Scott E. Strome(Northwestern Medicine Lake Forest Hospital), Erin Burch(Syngenta (United States)), Cinthia B. Drachenberg(University of Maryland, Baltimore), Henrik S. Olsen(Gliknik (United States)), David S. Block(Gliknik (United States)), Søren M. Bentzen(University of Wisconsin–Madison), Susan Kinsey(Gliknik (United States)), John C. Papadimitriou(University of Maryland, Baltimore), Edward So(University of Maryland, Baltimore), Emmanuel Y. Mérigeon(Gliknik (United States))
Cited by 18
Related Papers
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
The Banff 97 working classification of renal allograft pathology
|Kidney International|1999|3.1k
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
|American Journal of Transplantation|2008|1.9k
Pathologic Classification of Diabetic Nephropathy
|Journal of the American Society of Nephrology|2010|1.7k
Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions
|American Journal of Transplantation|2014|1.3k